Research

Hormonal

Weekly GLP-1 receptor agonists significantly reduce MACE risk in obese T2DM patients, whereas daily GLP-1 RAs do not show a significant reduction compared to placebo.

For obese diabetic patients, choosing a weekly GLP-1 injection (like dulaglutide or semaglutide) may offer better heart protection than daily options (like liraglutide or lixisenatide), according to this analysis. However, the difference between the two classes was not statistically significant when compared directly to each other.

ModerateQualifiesMEDIUM confidence
In the participants with obesity and T2DM, weekly GLP-1 RAs (exenatide, dulaglutide, albiglutide, and subcutaneous semaglutide) reduced the risk of MACE versus placebo (RR 0.87 [0.78–0.95]), whereas daily GLP-1 RAs (lixisenatide, liraglutide, and oral semaglutide) did not (RR 0.93 [0.78–1.10]).
Kazushi Uneda et al. · Scientific Reports · 2021

Why this rating

Sensitivity analysis of a subset of studies; heterogeneity was moderate to high.

Source

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Kazushi Uneda et al. · Scientific Reports · 2021

DOI 10.1038/s41598-021-89620-7

Meta-analysis · 12 studiesCited 25×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →